These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2076022)

  • 1. Antitumor enzyme: polyethylene glycol-modified asparaginase.
    Wada H; Imamura I; Sako M; Katagiri S; Tarui S; Nishimura H; Inada Y
    Ann N Y Acad Sci; 1990; 613():95-108. PubMed ID: 2076022
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of L-asparaginase: polyethylene glycol conjugate versus native L-asparaginase combined with chemotherapy. A randomized double-blind study in canine lymphoma.
    MacEwen EG; Rosenthal RC; Fox LE; Loar AS; Kurzman ID
    J Vet Intern Med; 1992; 6(4):230-4. PubMed ID: 1522554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyethylene glycol-L-asparaginase versus native L-asparaginase in canine non-Hodgkin's lymphoma.
    Teske E; Rutteman GR; van Heerde P; Misdorp W
    Eur J Cancer; 1990; 26(8):891-5. PubMed ID: 2145933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asparaginase revisited.
    Capizzi RL
    Leuk Lymphoma; 1993; 10 Suppl():147-50. PubMed ID: 8481663
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic factors for treatment of malignant lymphoma in dogs.
    Teske E; van Heerde P; Rutteman GR; Kurzman ID; Moore PF; MacEwen EG
    J Am Vet Med Assoc; 1994 Dec; 205(12):1722-8. PubMed ID: 7744644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma.
    Agrawal NR; Bukowski RM; Rybicki LA; Kurtzberg J; Cohen LJ; Hussein MA
    Cancer; 2003 Jul; 98(1):94-9. PubMed ID: 12833461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical modification of L-asparaginase with comb-shaped copolymer of poly(ethylene glycol) derivative and maleic anhydride.
    Saito T; Ueno T; Sekine T; Kodera Y; Hiroto M; Matsushima A; Nishimura H; Inada Y
    Leukemia; 1997 Apr; 11 Suppl 3():408-9. PubMed ID: 9209407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-asparaginase and PEG asparaginase--past, present, and future.
    Keating MJ; Holmes R; Lerner S; Ho DH
    Leuk Lymphoma; 1993; 10 Suppl():153-7. PubMed ID: 8481665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progress in researches on anti-tumor agent L-asparaginase for treatment of leukemia].
    Zhou J; Jin H; Li Y; Jiang T
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2000 Sep; 17(3):343-5. PubMed ID: 11285852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates.
    Abuchowski A; Kazo GM; Verhoest CR; Van Es T; Kafkewitz D; Nucci ML; Viau AT; Davis FF
    Cancer Biochem Biophys; 1984 Jun; 7(2):175-86. PubMed ID: 6467175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peg-asparaginase for acute lymphoblastic leukemia.
    Rytting M
    Expert Opin Biol Ther; 2010 May; 10(5):833-9. PubMed ID: 20345338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of asparaginase on a combination chemotherapy protocol for canine multicentric lymphoma.
    Jeffreys AB; Knapp DW; Carlton WW; Thomas RM; Bonney PL; Degortari A; Lucroy MD
    J Am Anim Hosp Assoc; 2005; 41(4):221-6. PubMed ID: 15995158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic pseudocyst in an adult patient after treatment with pegylated asparaginase.
    van Galen KP; Zweegman S; Ossenkoppele GJ
    Br J Haematol; 2011 Mar; 152(6):676. PubMed ID: 21623759
    [No Abstract]   [Full Text] [Related]  

  • 14. A preliminary study on the evaluation of asparaginase. Polyethylene glycol conjugate against canine malignant lymphoma.
    MacEwen EG; Rosenthal R; Matus R; Viau AT; Abuchowski A
    Cancer; 1987 Jun; 59(12):2011-5. PubMed ID: 3567863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaphylactic reaction to polyethylene-glycol conjugated-asparaginase: premedication and desensitization may not be sufficient.
    Sahiner UM; Yavuz ST; Gökce M; Buyuktiryaki B; Altan I; Aytac S; Tuncer M; Tuncer A; Sackesen C
    Pediatr Int; 2013 Aug; 55(4):531-3. PubMed ID: 23910807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia.
    Yoshimoto T; Nishimura H; Saito Y; Sakurai K; Kamisaki Y; Wada H; Sako M; Tsujino G; Inada Y
    Jpn J Cancer Res; 1986 Dec; 77(12):1264-70. PubMed ID: 3102431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two cases of pegylated asparaginase-associated severe and persistent hyperbilirubinemia.
    Kim S
    Am J Hematol; 2009 Oct; 84(10):696. PubMed ID: 19731309
    [No Abstract]   [Full Text] [Related]  

  • 18. L-asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia.
    Rathi B; Azad RK; Vasudha N; Hissaria P; Sawlani V; Gupta RK
    Pediatr Neurosurg; 2002 Oct; 37(4):203-5. PubMed ID: 12372914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased antitumor activity of Escherichia coli. L-asparaginase by modification with monomethoxypolyethylene glycol.
    Kamisaki Y; Wada H; Yagura T; Nishimura H; Matsushima A; Inada Y
    Gan; 1982 Jun; 73(3):470-4. PubMed ID: 6751921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidural hematoma in a patient on pegylated-L-asparginase therapy.
    Qubty WF; Mrelashvili A; Patterson MC
    J Child Neurol; 2015 Apr; 30(5):636. PubMed ID: 24396128
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.